Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Janet Anciro

Internal Medicine Melbourne, FL Medical Doctor

NPI 1578538278 CMS profile 207014

3972 W Eau Gallie Blvd Ste B, Melbourne, FL 32934

Open in the dashboard

General payments

$6,870

361 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Janet Anciro of Melbourne, FL is reported in the CMS Open Payments database as having received $6,870 across 361 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $858 39
2024 General $856 44
2023 General $985 52
2022 General $856 49
2021 General $1,195 64
2020 General $578 30
2019 General $1,542 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janet Anciro
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Janet Anciro were reported at $858. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Janet Anciro Internal Medicine median Middle half National median
2019 $1,542 $159 $48–$570 $163
2020 $578 $119 $33–$402 $114
2021 $1,195 $135 $37–$521 $132
2022 $856 $141 $42–$496 $149
2023 $985 $149 $45–$519 $160
2024 $856 $154 $47–$537 $164
2025 $858 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,595 94 payments
  2. AstraZeneca Pharmaceuticals LP $1,302 69 payments
  3. Lilly USA, LLC $638 29 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $508 27 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $455 31 payments
  6. Amgen Inc. $363 19 payments
  7. AbbVie, Inc. $350 17 payments
  8. Exact Sciences Corporation $326 13 payments
  9. Sanofi-Aventis U.S. LLC $248 12 payments
  10. Pfizer Inc. $225 11 payments
  11. Other $859 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,841 359 payments
  2. Education $29 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,181 80 payments
  2. RYBELSUS $950 56 payments
  3. FARXIGA $851 46 payments
  4. XIFAXAN $455 31 payments
  5. BREZTRI $373 18 payments
  6. Cologuard Collection Kit $296 12 payments
  7. UBRELVY $245 11 payments
  8. Otezla $211 11 payments
  9. JARDIANCE $208 12 payments
  10. EMGALITY $206 11 payments
  11. Other $3,618 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 142 drugs

Part D claims

7,454

Median for Internal Medicine: 777

Drug cost

$1,089,370

Median for Internal Medicine: $73,373

Branded share of claims

16.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hetlioz Tasimelteon Brand 13 $330,038
Ozempic Semaglutide Brand 85 $128,901
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 54 $92,348
Mounjaro Tirzepatide Brand 44 $67,265
Jardiance Empagliflozin Brand 46 $54,486
Rybelsus Semaglutide Brand 29 $45,762
Eliquis Apixaban Brand 36 $45,073
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $29,334
Tresiba Flextouch U-200 Insulin Degludec Brand 25 $25,826
Farxiga Dapagliflozin Propanediol Brand 16 $23,559

The 10 drugs with the highest cost, of 142 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$102,451

Medicare's payments for the services billed

Medicare patients

232

Average age 74

Services billed

1,205

159 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 41%
Ischemic heart disease 24%
Osteoporosis 21%
Chronic kidney disease 20%
Atrial fibrillation 18%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $172
$172 23 —
RYBELSUS
  • Novo Nordisk Inc $113
$113 29 —
Ozempic
  • Novo Nordisk Inc $105
$105 85 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $80
$80 16 —
Repatha
  • Amgen Inc. $46
$46 42 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

361 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record